IVIG and IMIG as upstream neuroinflammation modulators — where the evidence stands, why a new delivery route may be mechanistically preferable, and what a clinical trial would need to show.
See framework disclaimer belowSafety & Supervision — Required Reading
All interventions described on this page are investigational, off-label, and require qualified medical oversight. This framework is a research model — not a prescription. No supplement, immunological, or cellular therapy described here should be initiated without direct involvement of a physician who knows the individual patient. Forskolin and other cAMP-modulating agents carry specific cardiac and drug-interaction risks and must never be self-administered. MSC therapy and IMIG/IVIG are experimental for ASD in every jurisdiction and require specialist evaluation. When in doubt, consult before acting.
Every intervention in the Biology of Autism framework addresses a node somewhere along the cascade — from NAD⁺ precursors that restore mitochondrial energy to the six-layer infrastructure repair protocol that unlocks the G-protein cascade. Immunoglobulin therapy is different. It acts before the cascade loads at its convergent node — at the level of the cytokine environment that drives both IDO1 activation and NF-κB-mediated SST-14 interneuron silencing simultaneously.
The significance of this entry point is not merely positional — it is mechanistic. IMIG and IVIG address the inflammatory cytokine environment that is simultaneously driving both arms of SST-14 silencing. Treating the downstream neuropeptide deficit while the upstream cytokine burden remains active is addressing symptoms of a valve that has not been closed. For children with documented immune dysregulation, immunoglobulin therapy targets the valve itself.
Companion Working Papers
The mechanistic foundation for this page is developed in two companion working papers available at the Research Articles hub: The Anatomy of Autism — presenting the two-layer model of cascade mechanism and constitutional susceptibility architecture with seven tipping points, the CREB/CBP/CRE transcriptional suppression dual-mechanism, and the estrogen-cAMP sex ratio explanation; and Restoring the Somatostatin Signal in Immune-Dysregulated ASD — the companion paper from which this page's three-state model, biomarker trial framework, and adjunct protocol rationale are drawn. Both are working documents under expert review prior to journal submission.
IVIG has been studied in autism longer than almost any other biological intervention. A 2021 systematic review and meta-analysis by Rossignol and Frye, published in the Journal of Personalized Medicine, examined 27 publications reporting the therapeutic use of IVIG in individuals with ASD — including four prospective controlled studies, six prospective uncontrolled studies, and fifteen retrospective case series and reports.
"IVIG is a promising and potentially effective treatment for symptoms in individuals with ASD; further research is needed to provide solid evidence of efficacy and determine the subset of children with ASD who may best respond to this treatment as well as to investigate biomarkers which might help identify responsive candidates."
Rossignol & Frye, Journal of Personalized Medicine, 2021The consistent finding across studies is that gains are most pronounced — and most durable — in children with identified immune abnormalities: low total IgG, IgG subclass deficiency, elevated pro-inflammatory cytokines, specific polysaccharide antibody deficiency, or autoantibodies to brain proteins. This is not a treatment for autism broadly defined. It is a treatment for a biologically defined subpopulation in which immune dysregulation is a measurable, active driver.
One critical and consistent finding across multiple studies: when IVIG was stopped, gains were frequently lost. This is not an isolated observation from a single study — it appears across the literature wherever investigators followed outcomes after discontinuation. Boris et al. (2005, n=26) reported that 85% of treated children lost some improvements after stopping. Maltsev & Yevtushenko (2016, n=78) found that 50% of children with mild-to-moderate improvement lost their gains within 2–4 months of completing therapy. Plioplys (1998) documented complete regression in the one child who had shown a remarkable response when treatment was stopped. Knutsen & Fenton (1998) reported worsening of seizures when IVIG was discontinued in a child who had previously improved. The consistency of this pattern across studies, patient populations, and dosing protocols is itself informative: it is not a treatment failure. It is a signal that the underlying inflammatory process continues without ongoing modulation, and that durable benefit requires sustained immunomodulation rather than a completed course. The implication for trial design — and for understanding why a steady-state delivery route may matter — is significant.
IVIG and IMIG are not the same formulation. They differ in concentration, volume, route of administration, cost, and critically — in how serum IgG levels behave over time. IVIG is formulated at 5–10% IgG for intravenous infusion and produces a rapid, high peak in serum IgG within 24 hours. IMIG is formulated at 16.5% IgG for intramuscular injection in small volumes (1–5 mL) and produces a slower, lower, but more sustained IgG elevation.
IVIG vs IMIG — a pharmacokinetic distinction with clinical implications. IVIG produces a high serum IgG peak within 24 hours, then declines over 3–4 weeks, creating oscillating inflammatory suppression. IMIG delivers a slower, sustained IgG elevation — a steady-state profile that may be mechanistically preferable for cascade biology, where SST-14 transcriptional recovery, CREB/BDNF-dependent plasticity restoration, and autoantibody clearance all require weeks of consistently reduced neuroinflammation, not periodic windows of relief.
| Feature | IVIG — Intravenous | IMIG — Intramuscular |
|---|---|---|
| IgG concentration | 5–10% (large volume) | 16.5% (small volume, 1–5 mL) |
| Serum IgG kinetics | Rapid high peak, then 3–4 week decline back toward baseline | Slower rise, lower peak, sustained steady-state elevation |
| Administration setting | Infusion centre, IV access, medical supervision for hours | Outpatient IM injection — clinic or practice, monthly |
| Cost per course | $10,000–$25,000 per infusion (US); R50,000–100,000 (SA) | Materials cost approximately $50 per treatment (NBI Intragam, South Africa — repriced from prior below-cost supply). Comparable global product Beriglobin (CSL Behring, Switzerland) is $80 per equivalent dose. Both represent a fraction of IVIG at $10,000–$25,000 per infusion — accessible in resource-limited settings globally. |
| Anxiety burden | IV access, clinic environment — significant anxiety for many ASD children | Less invasive environment; easier for sensory-sensitive patients |
| Regulatory status (ASD) | Off-label — not approved for ASD in any jurisdiction | Investigational — no published RCT in ASD as of 2024 |
In 2024, the first published case report of intramuscular immunoglobulin specifically in ASD and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) appeared in Medical Research Archives (European Society of Medicine). The report describes a monthly IMIG protocol using Intragam (National Bioproducts Institute, South Africa, 16% IgG) administered at 0.2 mL/kg body weight intramuscularly on a 4–6 weekly basis.
The more modest ASD response compared to PANS is interpreted by the authors as a timing effect. In PANS, the autoimmune trigger is often acute and relatively recent. In ASD, neuroinflammation typically begins in early development — and by the time IMIG is initiated, structural neural changes may have already accumulated. The logical implication is that earlier intervention should produce a stronger response. This is a hypothesis that can be tested. It is also the reason why biomarker-guided patient selection — using the cascade framework's immune dysregulation markers — is central to any future trial design.
The existing evidence base — Rossignol & Frye's meta-analysis establishing IVIG's signal, and Fourie & Armstrong's first published IMIG case report — establishes proof of mechanism and preliminary clinical signal. What it does not yet provide is the controlled, biomarker-stratified evidence that would allow IMIG to move from investigational to accessible.
For context on the opportunity cost: a controlled pilot trial of this scope represents a fraction of the cost of a failed late-stage pharmaceutical trial — and produces data that could support regulatory approval for the first biologically targeted, affordable treatment for a defined ASD subpopulation. No such approved treatment currently exists anywhere in the world.
Not all immune-derived autism presents the same suppressive burden at the SST-14 interneuron level. The three-state framework identifies where along the silencing spectrum a patient sits — and determines what combination of interventions is required. States are not mutually exclusive; a patient may show characteristics of more than one. The dominant state guides the sequencing decision.
| State | Mechanism | Key biomarkers | Primary intervention |
|---|---|---|---|
| State 1 Transcriptional suppression |
NF-κB-mediated CREB inhibition and autoantibody surface receptor jamming. Interneuron structurally and metabolically intact. Gene expression machinery recoverable. | Elevated K:T ratio; cytokine elevation (IL-6, TNF-α, IL-1β); autoantibody panel positive; lactate:pyruvate normal (<20) | IMIG or IVIG — immune clearance is the rate-limiting intervention. Adjunct metabolic protocol running concurrently. Metabolic restoration not the primary constraint. |
| State 2 Metabolic exhaustion |
Mitochondrial failure from chronic quinolinic acid calcium overload and NAD⁺ depletion. Gene expression recoverable; energy substrate depleted. Phosphatidylcholine depletion from SAMe insufficiency degrades membrane integrity. | Elevated K:T ratio; elevated lactate:pyruvate (>25); low plasma NAD⁺; elevated 8-isoprostane; cytokine elevation | IMIG/IVIG + NAD⁺ precursors (NMN or NR) + mitochondrial support + methylation cycle restoration. Consider MSC trophic support for State 2 patients not responding to immune clearance alone. |
| State 3 Structural loss |
Partial SST-14 interneuron loss from sustained excitotoxicity. A1 astrocyte polarisation removes hevin/SPARCL1, BDNF, and synaptogenic trophic support. A1 state is not permanent — reversal occurs when inflammatory signals are removed (Liddelow et al., Nature 2017). | Elevated K:T ratio; low plasma BDNF; elevated lactate:pyruvate; A1 astrocyte markers elevated; reduced hevin/SPARCL1 where measurable | IMIG/IVIG + MSC trophic restoration (IGF-1, BDNF, A1→A2 polarisation shift). Immune clearance to halt further loss. Infrastructure protocol as foundation. Longest recovery timeline — but not irreversible. |
Why prior trials in unselected populations produced null results is directly explained by this framework. Unselected enrollment mixes State 1, State 2, State 3, and non-immune-derived ASD patients in approximately equal proportions. The responsive subgroup — State 1 and early State 2 — is diluted to statistical insignificance. The SOARS-B oxytocin trial (Sikich et al., NEJM 2021, n=290) and the secretin Cochrane review (14 null RCTs) both reflect this population-selection failure, not a failure of the underlying biology. The same principle applies to IVIG trials conducted without biomarker stratification.
Independent genetic evidence for the State 2 model comes from Dr. Eric Morrow's research at the Lurie Autism Institute on glutamate pyruvate transaminase 2 (GPT2). Loss-of-function mutations in GPT2 — the mitochondrial enzyme that clears synaptic glutamate by converting it to alpha-ketoglutarate for TCA cycle entry — produce intellectual disability and reduced brain growth. In State 2 SST-14 interneurons already NAD⁺-depleted by IDO1 activation, impaired GPT2 function compounds the metabolic failure that prevents the cAMP→PKA→CREB→SST-14 transcriptional cycle from being energetically sustained. Dr. Morrow's work establishes the genetic proof-of-concept that mitochondrial-glutamate dysfunction at the synaptic level causes neurodevelopmental disability — the same mechanism the State 2 model proposes is occurring in acquired form through IDO1/kynurenine pathway activation in the broader immune-dysregulated ASD population.
Convergent independent evidence for the upstream cAMP suppression mechanism comes from Robert Naviaux's cell danger response framework. Naviaux's 2017 phase I/II suramin trial (n=10) produced improvement across all three core ASD domains in all five treated participants at 6 weeks — with gains lost after suramin's 14–15 day half-life as upstream drivers continued. Suramin antagonizes P2Y receptors that couple through Gαi to suppress adenylyl cyclase — the identical Gαi-adenylyl cyclase suppression mechanism the cascade framework describes through the adenosine/CD26 arm. The CDR and the three-state SST-14 model represent convergent evidence from independent research lineages arriving at the same biological territory: G-protein cascade failure, mitochondrial exhaustion, and hypothalamic neuropeptide suppression.
IMIG modulates the upstream immune environment. The adjunct metabolic protocol addresses the intracellular cascade consequences that have accumulated while that immune environment was active. Neither is sufficient alone: IMIG without intracellular repair leaves the downstream infrastructure unable to transmit the signals that immune clearance enables; intracellular repair without immune clearance works against an ongoing inflammatory driver that continuously reasserts the suppressive burden. The two protocols are mechanistically complementary, not alternatives.
| Agent | Mechanism target | Cascade node addressed |
|---|---|---|
| Sulforaphane Highest priority |
Nrf2 activation → GSTP1 upregulation → glutathione conjugation → reduced membrane lipid peroxidation (GPCR coupling restoration). NF-κB suppression → reduced cytokine-driven PDE4 upregulation → longer cAMP signal duration. Blood-brain barrier penetration — acts centrally where the NF-κB-mediated SST-14 transcriptional suppression is occurring. | BP1 membrane oxidation; BP4 PDE4 loop; BP3 adenosine axis (via reduced inflammatory ATP demand) |
| NAC + Glycine | NAC provides cysteine (rate-limiting glutathione precursor). Glycine provides the third glutathione amino acid. Together they restore the glutathione pool depleted by the transsulfuration bottleneck of methylation cycle failure. Glycine is also an NMDA co-agonist — relevant to quinolinic acid NMDA overactivation at SST-14 interneurons. | Glutathione restoration; transsulfuration pathway; NMDA receptor co-agonism |
| NMN or NR (NAD⁺ precursors) |
Direct NAD⁺ precursor supplementation restores the mitochondrial energy substrate depleted by IDO1 overactivation and consumed by mitochondrial stress responses. Particularly important for State 2 patients where NAD⁺ depletion has reached the level of compromising tonic SST-14 interneuron firing. | NAD⁺ depletion; mitochondrial ATP production; State 2 metabolic exhaustion |
| Magnesium (glycinate or malate) |
Essential cofactor for carbonic anhydrase (gastric HCl production), AHCY (SAH clearance), myokinase salvage (2ADP→ATP+AMP), and PKA-mediated phosphorylation. Addresses the adenine nucleotide pool at three breaking points simultaneously. Glycinate form provides additional glycine for glutathione synthesis. | BP2 GTP pool; BP3 AC substrate; BP5 PKA phosphorylation; gastric pH restoration |
| Luteolin-PC (phosphatidylcholine complex) |
Luteolin targets both NF-κB (reducing cytokine-driven SST-14 transcriptional suppression) and CD38 (the primary NAD⁺-consuming enzyme during immune activation). The phosphatidylcholine complex improves bioavailability and provides PC directly — the SAMe-dependent mitochondrial membrane phospholipid that SAMe depletion has reduced. | NF-κB / CREB suppression; NAD⁺ conservation; mitochondrial membrane integrity |
| Tributyrin / Butyrate | Butyrate is an HDAC inhibitor and NF-κB suppressor produced by commensal gut bacteria from dietary fiber. It reduces the gut-origin inflammatory signal feeding systemic immune activation, calms microglial reactivity, and supports intestinal barrier integrity — reducing LPS translocation that maintains the cytokine burden driving both IDO1 and NF-κB CREB suppression. | Gut barrier integrity; LPS translocation; NF-κB suppression; microglial calming |
The sequencing principle: infrastructure repair begins immediately and runs concurrently with IMIG from the first treatment cycle. The supplement protocol does not wait for IMIG to produce immune clearance — it prepares the intracellular environment so that when immune clearance begins, the downstream signalling infrastructure is progressively more capable of transmitting the signals that reduced inflammatory burden enables. See Unlocking the Brake for the full six-layer infrastructure repair sequence.
Mesenchymal stem cell (MSC) therapy has attracted growing research interest in ASD. Understanding how it relates to IMIG requires understanding what each intervention actually does at the mechanistic level — because they address different nodes in the cascade and are most appropriately understood as complementary rather than competing approaches.
| Feature | IMIG / IVIG | MSC Therapy |
|---|---|---|
| Primary mechanism | IgG-mediated immunomodulation: neutralises pathological autoantibodies against SST-14 interneuron surface proteins; suppresses pro-inflammatory cytokine production (IFN-γ, TNF-α, IL-6, IL-1β); modulates NK cell and T-cell activation profiles; reduces the cytokine load driving both IDO1 excitotoxic arm and NF-κB transcriptional suppression arm of SST-14 silencing. | Paracrine trophic support: MSCs do not engraft or replace neurons. They secrete IGF-1, BDNF, hepatocyte growth factor, and prostaglandin E2. They also shift astrocyte polarisation from A1 reactive toward A2 homeostatic — restoring hevin/SPARCL1 and synaptogenic support. Anti-inflammatory through IDO and PGE2 secretion, not through IgG-mediated mechanisms. |
| State indication | State 1 (primary); State 2 (primary + metabolic support); State 3 (combined with MSC) | State 2 (adjunct where metabolic exhaustion is rate-limiting); State 3 (primary addition — trophic restoration for interneuron populations that have lost their BDNF and synaptogenic environment) |
| What it does not address | Does not restore depleted NAD⁺, mitochondrial energy substrate, or trophic factors for surviving interneurons. Does not reverse A1 astrocyte polarisation directly — reduces the microglial signals driving it, allowing A2 recovery over time. | Does not clear pathological autoantibodies against SST-14 interneuron surface receptors. Does not directly suppress the cytokine-driven NF-κB CREB suppression operating at the transcriptional level. Does not reduce the IDO1 excitotoxic quinolinic acid production. |
| Evidence base in ASD | Rossignol & Frye 2021 meta-analysis (n=46 meta-analysis, 27 publications); Fourie & Armstrong 2024 IMIG case report; multiple prospective and retrospective studies. | Preliminary — several small open-label trials showing safety signals and modest behavioural improvements. No published RCT in ASD as of 2025. Larger controlled studies underway. |
| Cost and access | IMIG: approximately $50–80 per treatment (NBI Intragam / Beriglobin equivalent). Monthly outpatient administration. Scalable globally including resource-limited settings. | Substantially higher — typically $5,000–$20,000 per treatment course. Requires specialised cell therapy facility. Access currently limited to research centres and private clinics. |
The clinical decision logic: IMIG is the appropriate first-line biological intervention for biomarker-confirmed immune-derived autism across all three states — it addresses the upstream immune environment driving SST-14 silencing regardless of state. MSC therapy is the appropriate addition for State 2 patients not responding adequately to immune clearance alone, and the primary trophic addition for State 3 patients where interneuron population loss requires active restoration of the trophic environment. Running both simultaneously in State 3 addresses the cascade from two mechanistically independent directions: immune clearance halts ongoing damage while MSC trophic support rebuilds the environment for recovery.